Today at the Cardiovascular Research Technologies (CRT) annual conference taking place in Washington, DC, Dr. Christopher Chieh Yang Koo from National University Hospital Singapore, ...

Plus Therapeutics will present ReSPECT-LM trial results and host a symposium on leptomeningeal metastases at the SNO/ASCO conference. Announcement of the oral presentation of ReSPECT-LM clinical trial ...

Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San Francisco Travelan® on display at HealthEd Australian Travelan® sales continue to grow, with a Q1 CY19 ...

Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ...

BRANFORD, Conn., May 28, 2025 /PRNewswire/ -- Azitra, Inc. (AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, ...

Event details are available on the Immix website in the Presentation & Events section at https://immixbio.com/investors/#investor-presentation. About AL Amyloidosis ...

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ...

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have ...

First podium presentation of IDE Clinical Trial Data of Novel Embolic Device to Treat Cancer The SIR clinical community will be key users of our next-gen gel embolic materials and we are excited that ...

On May 20, 2024, the National Academies Forum on Drug Discovery, Development, and Translation in collaboration with the National Cancer Policy Forum, convened a public workshop for stakeholders to ...